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A field trial was conducted to determine the effect of vacci-
nation with an inactivated bovine herpesvirus 1 (BHV1) gE-neg-
ative marker vaccine on the milk production of dairy cows. The
daily milk yield of 455 cows in six herds was measured electron-
ically from six days before vaccination until 14 days after vacci-
nation. The treatment consisted of two injections with either
vaccine or placebo, both at an interval of four weeks. There was
a small, but significant (P<005), decrease of about 1f4 litres per
cow in milk production after a double vaccination, the negative
effect being slightly greater after the second vaccination.
BEFORE a new vaccine can be registered and released, it has to
fulfil the requirements of official documents, such as the
European Pharmacopoeia, which stipulate standards for the safety
and efficacy of medicinal products.
According to the directives of the European Union, an investi-
gation of safety aspects has to demonstrate the possible adverse
effects of a medicinal product under practical conditions of use
(Commission Directive 92/18/EEC). In safety investigations, not
only local and systemic reactions are measured but also the ani-
mal's performance. The daily milk production of lactating cows is
a good indicator of performance, because potential decreases in
milk production after vaccination can have an economic impact.
Bovine herpesvirus 1 (BHvi) is an economically important
pathogen for cattle, causing infectious bovine rhinotracheitis (IBR)
and infectious pustular vulvovaginitis (iPv). Attenuated and inacti-
vated virus vaccines are used- to control BHVI infection. There have
been few investigations of the adverse effects of these BHVI vac-
cines. One investigation of the intramuscular injection of an attenuat-
ed BHVI combination vaccine (Cortese 1991) showed no significant
differ-ences in milk production between small groups of vaccinated
and control animals during a short period. On the other hand, the
animal industry has great interest in good field trials (Baars and
Egger 1993).
Recently, several BHVI marker vaccines, which make it possible
to differentiate between vaccinated and field virus-infected ani-
mals serologically, have been developed (Drunen Littel van-Hurk
van den and others 1993, 1994, Kaashoek and others 1994, 1995).
These vaccines lack at least one protein that is present in the cor-
responding wild-type virus and they could play an important role
in BHVi eradication programmes (Lemaire and others 1994, Strube
and others 1995). This paper describes a field trial to determine
the effect, on milk production, of vaccination with a novel inacti-
vated BHVI glycoprotein E-negative marker vaccine.
Materials and methods
Farms
The study was carried out on five farms belonging to Dutch cat-
tle research centres, with standardised management. One farm had
two separate herds. Holstein-Friesian breeds dominated five of the
herds, and the other herd was of the Meuse-Rhine-Yssel breed.
The smallest herd had 49 cows.
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All 455 lactating cows in the six herds were used. On two farms
all the cows were seropositive to BHV1 in a commercially avail-
able ELISA (Svanova). The other four herds were BHVi-positive in
a bulk milk sample (Svanova). Some animals in three herds were
known to have been vaccinated as yearlings with a modified live
non-marker vaccine.
Allocation oftreatment
In each herd, the cows were listed according to their most
recent calving date and pairs of consecutively listed animals were
formed. From each pair, one animal was randomly allotted (by the
drawing of lots) to either group 1 or group 2, and the other was
then assigned to the other group. Next, the treatment with vaccine
(v) or placebo (P) was randomly assigned to group 1 or 2. In each
herd both treatment groups were mixed.
Treatment
Group 1 received the vaccine Bayovac (Bayer). Each dose con-
tained log 108.8 TCID50 inactivated gE-negative killed BHV1, strain
Za, and 2 ml of adjuvant consisting of aluminium hydroxide and
Quil A. Group 2 received 2 ml phosphate buffered saline (PBs) as
placebo (Kaashoek and others 1995). The vaccine and the placebo
were injected subcutaneously. The first injection was given in
June 1993 and the second was given four weeks later.
Measurements
Daily milk production was measured electronically, in milli-
litres, from six days before vaccination until 14 days after vacci-
nation. These daily milk productions are abbreviated as MP-6 to
MP14; MP-6 to MP-1 being the pre-vaccination yields.
Vaccination was carriea out on day 0. Owing to failures in the
automatic milk recording, it was decided not to use MP12 to
MP14. Body temperature was measured electronically from two
days before until 10 days after vaccination in 63 cows in two of
the herds; the measurements were made daily at 08.15.
Statistical analysis
To measure the effect of vaccination, the mean post treatment
yield was subtracted from the mean pre-treatment yield, the differ-
ence being abbreviated as aMP (delta milk production). To calcu-
late the mean pre- and post treatment yield, restrictions were
placed on the number of missing values. When in the pre-treat-
ment period three or more values for the daily milk production
were missing, the observation was deleted. This procedure was
thought necessary to stabilise the variance of the mean pre-treat-
ment yield. The post treatment period was from one to 11 days,
resulting in 11 dependent variables, 8MP1 to aMP I1. For 6MPI
and 6MP2, both MPl and MP2 had to be available. For 8MP3 to
6MP8 one missing value in MPI to MP8 was allowed and for
8MP9 to SMP 1I no more than two missing values were allowed
inMPl toMPIl.
A repeated measures model was used in order to take the cow
effect into account (each cow had two observations). A balanced
data set was created by using only those cows having a valid
observation for both the first and second injection.
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TABLE 1: Numbers of animals and mean milk productions of each
group before each treatment
Number of Daily milk production
Injection Treatment cows before treatment (litres)
1 Placebo 182 25-0
1 Vaccine 190 24.0
2 Placebo 176 22-9
2 Vaccine 181 21-8
The main effect model was:
6MPxijkl
6MPX
TRi
HERDj
eijk
INJI
e2ijkl
= constant + TRi + HERDj + eijk + INJI + interactions +
e2z j-k
difference in milk production before and after treat-
ment (x = 1 to 11)
: effect of treatment (i = 1 and 2 for groups V and P,
respectively)
: effect of herd (j = 1 to 6)
: error term 1, which represents the random effect of
cow nested within treatment i and herd j (k = cow
number)
: effect of first or second injection (1 = 1 or 2)
: error term 2
Treatment and herd effects and their interaction were tested
against error term 1. The effects of injection and other interactions
were tested against error term 2. If they were not significant, any
interaction effects were omitted stepwise from the model, starting
with the three-way interaction TR*HERD*INJ. Main effects were
always included, irrespective of the significance. The analysis
used PROC GLM of SAS (SAS 1990). The statistical significance
level was chosen as P<0-05.
Results
Data editing
The initial data set included production data from 455 animals.
The 21 cows which received a first injection only were deleted
from the data set as well as the 18 cows that entered the herds
between the first and second injection. Records from the 31 cows
which had been lactating for less than 21 days on the first day of
measurement were also deleted in order to exclude major effects
of parturition. The 16 lactations exceeding 335 days were also
removed.
As a result of the restrictions on the number of missing values
for daily milk production before treatment, 75 cows were delet-
ed. Varying numbers of cows were removed from the data set
owing to restrictions on the number of missing values in daily
milk production after treatment. Depending on the latter and the
prerequisite for balance, the minimum number of cows in the
analysis was 236 (472 injections) and the maximum 283 (566
injections).
TABLE 2: Differences in the estimated daily milk production per cow
between the vaccinated and placebo-treated groups and its signifi-
cance, measured at various periods after treatment
Length of post
treatment period Number of Difference in mean
(days) observations milk production (kg/day) P
1 542 0-54-0-09 = 0-45 <0-01
2 522 0-62-0.22 = 0-40 <0.01
3 566 0-64-0-28 = 0-36 <0.01
4 558 0-66-0-36 = 0-30 0.01
5 520 0.74-0-48 = 0-26 0-03
6 494 0.81-0.58 = 0-23 0-05
7 480 0-81-0.60 = 0-21 0-10
8 472 0860-66 = 0-20 0-12
9 560 0-89-0-72 = 0-17 0-28
10 552 0-90-0-77 = 0-13 0-47
11 534 0-92-080 = 0-12 0.33
Data analysis
Table 1 shows the numbers of animals and the daily milk pro-
duction per cow before the treatment of the placebo and vaccine
groups. Despite the random allocation of pair members to groups,
the placebo group gave on average 1 litre/day more milk than the
vaccine group before the first treatment and the difference was
about the same at the second treatment. The decrease of about 2
litres in the daily milk production before treatment between the
first and the second injection can be explained by the fact that
most of the animals had passed the top of the lactation curve.
The resulting statistical model was equal for 6MP1 to 8MP 1.
The three-way interaction TR*INJ*HERD and the two-way inter-
actions TR*INJ and HERD*TR were not significant, but the inter-
action HERD*INJ was included in all the models. There was a
significant effect of vaccination (P<0-05) on mean milk produc-
tion during the first six days after treatment (R2 = 0-63). The
effect was estimated as 0-23 litres/day. Therefore, the initial esti-
mate of the effect of vaccination on total milk production in the
first six days after treatment was about 0-23 x 6 = 1-4 litres per
animal per vaccination. Furthermore, Table 2 shows that the dif-
ference in milk production levelled out after day 6. To check
whether this difference already existed before the treatment was
given, the six days before treatment were divided into two periods
of three days each and these periods were analysed as pre- and
post treatment periods. The difference between the daily milk pro-
duction during these new pre- and post treatment periods was 0-14
litres (based on 307 cows, P<0-15), which is about equal to the
level of the difference in mean milk production after day six post
treatment. The actual reduction in milk yield due to vaccination
was thus 6 x (0-23-0-14) = 0-54 litres per animal per vaccination.
However, this does not mean that the milk production per day was
negatively affected during those six days. By the first day after
vaccination the effect was estimated as (0-45-0-14) = 0-3 litres
(P<0-05). A separate analysis using only MP2 showed that the
effect on that day was (0-35-0-14) = 0-2 litres (P<0-05). The
(adjusted) effect at day 3 was 0-2 (P<0-05) but it was not signifi-
cant on the subsequent days. Based on the daily milk yield, the
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total loss in milk production was about (0-3+0-2+0.2) = 0-7 litres
per cow per injection which is about equal to the calculated loss
using 6MP3, 3 x (0-36-0-14) = 0-66. The influence of the rank
number of vaccination during the first six days after treatment was
0-38 and 1-00 litre for the first and second injection, respectively.
The mean daily temperatures of the placebo and vaccine groups
after the first and second treatment are shown in Figs 1 and 2. The
difference in temperature between the placebo and vaccine group
one day after the first treatment was 0-45°C (P=0.02). One day
after the second treatment the difference was 0-26°C (P=0-06).
Discussion
Under normal conditions, the daily milk yield is highly variable
and, even in well-managed herds, a variation of 10 per cent has
been reported (Michel and others 1982). Thus in order to detect
smaller effects on milk yield large numbers of animals must be
studied (Michel and Mulholland 1981).
Several methods had been described for measuring the influ-
ence of a medicinal product on milk production. Some investiga-
tors have compared the adjusted milk productions of treated and
untreated groups (Spence and others 1992, Barkema and others
1994), whereas others have compared the actual milk production
with a predicted standard lactation curve (Michel and others 1982,
Ploeger and others 1990; Barlett and others 1991). To predict such
a lactation curve, several mathematical models have been devel-
oped (Masselin and others 1987).
Because the lactation curve of Wood (1967) is one of the most
frequently used deterministic models (Masselin and others 1987),
an attempt was made to use this model on the present data. An
average lactation curve was estimated for the unvaccinated ani-
mals. Deviations from this curve, before and after vaccination,
were calculated for the vaccinated animals, assuming that they
would have the same curve as the unvaccinated animals. The dif-
ference between the deviations before and after treatment was
then used as the outcome variable.
However, the estimated coefficients of the lactation curves var-
ied considerably between herds and between individual animals
within herds. However, only 20 daily measurements of milk pro-
duction per cow were available. As a result, a direct comparison
between the milk production before and after treatment was
deemed more appropriate, using the placebo group to indicate
possible trends in the population.
A very mild adverse effect of vaccination on mean milk pro-
duction was observed during the first six days after injection
(Table 2). The effect became significant because of the large num-
ber of animals. The decrease in milk yield was slightly larger after
the second injection. The total production loss of about 1-4 litres
for a double vaccination had occurred within the first three days
after injection. As a result, if the period after injection is relatively
long, even large short-term effects would not be detected by using
the mean milk production during that period.
A slight difference was observed between the calculated effect
of vaccination using the mean milk production (2 x 0.54 litres)
and the total loss in milk production based on daily milk yield (2 x
0-7 litres). This difference was due to the fact that different num-
bers of animals were used for the different calculations (Table 2).
The power of this study (1-type 2 error), indicating the probability
that the observed small treatment difference was a real difference,
was computed to be almost0-9.
After six days, the difference in the mean milk production was
due to the systematic difference between the vaccine and placebo
group. This large difference in milk production between the two
groups had been observed before the treatment and was larger
than expected, because the pair-members were allotted to the
groups at random (Table 1). This systematic difference was esti-
mated as0-14 litres/day.
Little has been published about the influence of vaccination on
milk yield because the effect should be only mildly adverse.
Cortese (1991) investigated the effect of a modified live BHV1
combination vaccine on the milk yield of 939 cows in 18 herds.
Milk production was measured for six milkings, three before and
three after vaccination. The results were tabulated in several ways,
including comparisons in individual herds of vaccinated cows
with unvaccinated controls. No significant differences between
the controls and the vaccinated cows were found, nor did signifi-
cant interactions occur between treatment and pregnancy, or vari-
ous ages or stages of lactation. Unfortunately, the report did not
describe the statistical method used.
Kahrs and others (1973), in a study of the effects of a modified
live IBR-parainfluenza (BHV1/PI3) vaccine, detected a slight
decrease in milk production in one of 12 herds, on the basis of
superficial inspections of daily milk weights.
An investigation on the adverse reactions of a capripox vacci-
nation in cattle was conducted by Yeruham and others (1994).
After the initial post vaccination reactions, which lasted for six
days, 442 cows in two dairy herds were closely monitored. Milk
yields before and after vaccination were compared and a decrease
in milk production of 3-5 per cent over a period of 12 days was
recorded. No placebo group was used. The initial post vaccination
reactions were not described.
In this study, an inactivated BHVI vaccine with adjuvant was
used. Since adjuvants frequentlycause adverse reactions (Vomand
and Sumano 1990), the adjuvant used in theBHVI marker vaccine
might have been responsible for the slight decrease in milk pro-
duction. However, there were no indications of severe adverse
system reactions in two of the herds after the first and second
treatment (Figs 1 and 2). The mild, but significant, temperature
reaction after the first vaccination was accompanied by a small
decrease in milk production. In contrast, after the second vaccina-
tion a negligible increase in temperature was accompanied by a
larger decrease in milk production.
The goal of the trial was to investigate the possible adverse
effects on milk production of the total vaccine, which is now used
in practice as such. Therefore, it was decided not to use the adju-
vant as the placebo. Few, if any, of the vaccines on the market
have been subjected to such a thorough study as this BHVI gE-neg-
ative marker vaccine. The results of this trial show that vaccina-
tion had a significant but negligible negative effect on mean milk
production for six days. The inactivatedBHVI gE-negative marker
vaccine is therefore safe with regard to its effects on milk produc-
tion. The results of this trial confirm that in order to detect the
possible small effects of vaccination on milk production, any trials
must be large scale and use sensitive and appropriate statistical
analyses to detect them.
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Prevention of surgical infections in dogs with
a single intravenous injection of marbofloxacin:
an experimental model
P. Gruet, P. Richard, E. Thomas, A. Autefage
Veterinary Record (1997) 140, 199-202
Eighteen healthy beagle dogs of both sexes were each given
0, 2 or 4 mg/kg marbofloxacin intravenously before the subcu-
taneous implantation of a silicon tissue cage. Two millilitres of
a suspension containing 1F3 x 104 colony forming units (CFU)/ ml
of Staphylococcus intermedius were then injected into the cage
15 minutes after the intravenous injection. The dogs were clini-
cally assessed immediately, and then two, four, eight and 24
hours after the challenge. Samples of inflammatory fluid were
harvested at the same times in order to count staphylococci and
to assay marbofloxacin concentrations. Blood samples were
taken in order to assay plasma marbofloxacin levels. The
staphylococcal counts were lower in both treated groups than
in untreated dogs (P<0-01). All the clinical criteria were similar
in the three groups. The concentration of marbofloxacin was
similar in plasma and inflammatory fluid. Both doses were well
tolerated and no adverse reactions were observed.
PREVENTION of infection in surgical wounds is a challenge to
all surgeons because true surgical asepsis can never be achieved.
Many efforts have been directed at reducing contamination at the
operation site and preventive techniques are now well described
(Romatowski 1989) and quite effective. Recorded infection rates
are low and comparable in veterinary and human surgery, with
overall rates of 5-1 per cent (Vasseur and others 1988) and 4-7 per
cent (Cruse and Foord 1980), respectively, for all types of surgery.
Numerous papers have been published reporting clinical results of
antimicrobial prophylaxis of surgical infections, both in the veteri-
nary and human fields, but with controversial conclusions. The
best way to provide accurate and well-controlled results is through
experimental models, because of the very low infection rates
recorded in practice. Several models have been described (Burke
1961, Bowers and others 1973, Scher and Jones 1985, Rosin and
others 1989, Kaiser and others 1992, Rosin and others 1993), but
most of them require the sacrifice of the animals concerned.
Ethical and practical considerations led the authors to develop a
more conservative approach to test a new antibacterial agent in the
prevention of surgical wound infections.
Marbofloxacin is a bactericidal antimicrobial agent belonging to
the family of fluoroquinolones that has been specifically developed
for veterinary medicine. It has recently been registered in several
European countries. Marbofloxacin has a broad spectrum of activi-
ty including the major pathogens encountered in surgical infec-
tions, in particular Enterobacteriaceae and staphylococci (Van Der
Bogaard and Weidema 1985, Moissonnier 1990, Spreng and others
1995). Moreover, marbofloxacin has pharmacokinetic properties of
particular interest in the prevention of surgical infection, it has a
very long elimination half-life, close to 14 hours in dogs
(Schneider and others 1996), and its tissue diffusion is excellent:
the ratio between tissue and plasma concentrations is 1.6 in muscle
and skin and even higher in liver (2-5) and kidney (2-3). These
properties are of particular importance and explain the good results
obtained in field trials involving canine skin infections (Carlotti
and others 1995) and urinary tract infections (Cotard and others
1995). In addition, marbofloxacin has been shown to be very safe
in dogs, with no articular damage when administered to juvenile
dogs at a dose of 6 mg/kg per day for three months (unpublished
observations). In this study, marbofloxacin was used in the form of
a 2 per cent injectable solution. An intravenous injection of 2 or 4
mg/kg marbofloxacin maintains plasma concentrations above the
minimum inhibitory concentrations (MIcs) of the major pathogens
(Enterobacteriaceae and staphylococci) for 12 to 24 hours.
The aim of this study, performed according to the standards of
Good Laboratory Practice, was to select an effective and safe dose
of marbofloxacin to prevent surgical infections in dogs.
Materials and methods
Experimental design and test system
Eighteen healthy beagle dogs were selected and randomly
assigned to three groups of six animals and two periods of time
(three animals per group per period of time), in a complete-block
design. The blocks were constituted to ensure homogeneity
between groups. All the animals were tattooed and recorded on
the 'Societe Centrale Canine' file. They were fed a standardised
diet and water was available ad libitum.
Experimental model
All the dogs were clipped at the incision site before the study
began.
Tissue cages. - The tissue cages consisted of 60 mm long Silastic
tubes (515-019; Dow Coming) of 12-7 mm external diameter and
9-5 mm internal diameter. Both ends were sealed with silicon glue
and holes were opened along the tube to let inflammatory fluids
in. The cages were sterilised by autoclaving.
Bacterial strain used for the experimental infection. - A
Staphylococcus intermedius strain isolated from a naturally occur-
P. Gruet, DVM, P. Richard, DVM, E. Thomas, DVM, Vetoquinol
Research Centre, BP189, F-70204 Lure Cedex, France
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